Angiochem and GlaxoSmithKline

Licensor: Angiochem
Licensee: GlaxoSmithKline
Deal size: $300 million
Upfront: Undisclosed
Milestones: $268.5 million
Stage: Discovery
When: February 12

What: Several years ago GSK ($GSK) made clear that it sees a big future for itself in the rare disease arena, and earlier this year its ambitions in the field led it to ink a development pact with the Montreal-based Angiochem, which has been working on enzyme replacement therapies that can penetrate the blood-brain barrier and treat CNS disorders.  In this collaboration Angiochem will develop an ERT for a lysosomal storage disorder. And if GSK likes what it sees, it has the right to expand the deal with new programs. The pact provides up to $31.5 million in upfront cash, research funding and other fees if GSK accesses the few LSD targets available to the collaboration.

Angiochem and GlaxoSmithKline